Tarsus Presents New Findings From Two Studies That Demonstrate the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

Tarsus Pharmaceuticals, Inc. presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on the coexisting bacterial burden for patients with Demodex blepharitis. Both studies were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

Accepted abstracts include:

• The Impact of Demodex Blepharitis on Patients and Healthcare System: Results from the Atlas Continuation Study; Blake Simmons, OD, et al.
• Demodex Blepharitis and Coexisting Bacterial Burden in Eye Care Patients: The Pandora Study; Kiersten Snyder, MD, et al.

“This research reinforces the significant burden and clinical impact of Demodex blepharitis, particularly among the most commonly seen patients in eye care practices,” said Bobak Azamian, MD, PhD, president and CEO of Tarsus. “We also recently announced strong, positive topline results from our second pivotal trial, Saturn-2, studying our lead investigational therapeutic, TP-03, for the treatment of Demodex blepharitis. With this positive data, we plan to submit a New Drug Application to the US FDA later this year, which is exciting for eye care professionals and the millions of patients suffering from this disease without an effective treatment option. We are committed to advancing our path forward to bring a potential definitive standard of care to these patients in need.”